Skip to main
  1. Stocks
  2. Structure Therapeutics Inc
  3. Forecast
GPCR

GPCR Stock Forecast & Price Target

GPCR Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 70%
Buy 30%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Structure Therapeutics is supported by compelling clinical evidence that aleniglipron delivered durable weight loss through 72 weeks, reaching up to 16.2% with no plateau, while also showing improved tolerability from lower-dose initiation and favorable liver safety with no DILI or Hy’s Law events. The company’s Phase 3 ACCOMPLISH program, enrolling up to 3,600 patients in obesity and up to 1,100 in obesity/T2D, adds a major de-risking catalyst, and management expects >$8B in worldwide peak sales potential. Beyond aleniglipron, ACCG-2671 showed target engagement, dose-proportional PK, and up to 3.3% weight loss after a single dose, broadening the pipeline and strengthening the long-term oral GPCR thesis.

Bears say

Structure Therapeutics is facing substantial clinical, commercial, and financial risk despite promising Phase 2b data for aleniglipron, because those mid-stage results still must be replicated in larger Phase 3 trials and may not hold up under broader testing. Competition is also intensifying, with several approved GLP-1 therapies and more than 20 programs in development, so aleniglipron must show a clearly differentiated efficacy and tolerability profile to win share against entrenched big pharma products. Meanwhile, the company is expected to keep incurring net losses until commercialization and likely through the early launch phase, raising the possibility of additional capital raises and uncertain dilution for shareholders.

GPCR has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 70% of analysts recommend a Strong Buy, 30% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Structure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

GPCR Analyst Forecast & Price Prediction

Get the latest GPCR stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in GPCR

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Structure Therapeutics Inc (GPCR) Forecast

Analysts have given GPCR a Strong Buy based on their latest research and market trends.

According to 10 analysts, GPCR has a Strong Buy consensus rating as of Nov 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $106.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $106.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Structure Therapeutics Inc (GPCR)


GPCR Analyst Forecast & Price Prediction

Get the latest GPCR stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in GPCR

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover GPCR stock data and trends